Herit

Quick links to important sections

Herit

Method of action: Throat Preparations

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Herit

Quick Facts

Property Description
Active Ingredient Tyrothricin (complex of Tyrocidine and Gramicidin)
Form Topical Solution, Spray, Lozenges
Pharmacological Class Polypeptide Antibiotic; Antimicrobial Agent
Common Use Localized bacterial infections of the mouth, throat, or skin
Origin Natural (bacterial-derived)

What is Herit and What Class of Medicine Does It Belong To?

Herit is a specialized, dermo-stomatological medicine designated strictly for local use on the skin or mucous membranes, placing it within the category of Antimicrobial Agents. It is specifically classified as a Polypeptide Antibiotic intended to fight bacteria locally. The drug's classification acknowledges its highly targeted application; it functions to concentrate its bacteria-fighting power directly at the site of application. Tyrothricin is a topical antibacterial agent suitable for managing discomfort associated with localized infections in areas like the throat, such as managing symptoms of a bacterial sore throat. Herit's primary purpose is to help cleanse localized affected areas and relieve discomfort associated with superficial bacterial contamination.


Composition, Origin, and Action Type (Bactericidal)

The core active ingredient in Herit is Tyrothricin (INN), a complex consisting of two principal natural substances: Tyrocidine and Gramicidin. This substance is of natural origin, having been isolated from the growth of the soil bacterium Brevibacillus parabrevis. The mechanism of the Tyrothricin complex is defined as bactericidal, an action which works to rapidly destroy the structural integrity of the bacterial cell wall and membrane. This powerful effect is potent but confined to the surface due to the compound's very poor absorption across mucous membranes and skin. This property makes Herit a localized agent, minimizing the risk of systemic exposure while providing antimicrobial efficacy where it is applied.


Common Pharmaceutical Forms and Route of Administration

Herit is available in several dosage forms optimized for targeted delivery, including topical solutions, sprays, and lozenges. The designated route of administration for all these preparations is exclusively topical—applied to the affected surface of the skin (cutaneous) or the lining of the mouth and throat (oromucosal). The composition ensures the active Tyrothricin complex is delivered in a suitable vehicle, such as an aqueous or hydroalcoholic solution, guaranteeing the medicine remains confined to the surface to maximize local concentration and therapeutic benefit.

Regulatory References

  1. Brevibacillus parabrevis
  2. Gramicidin

What side effects are possible with Herit?

Possible Side Effects and Safety Information

The safety profile of Herit (Tyrothricin) is characterized by its localized application, consistent with its classification as a polypeptide antibiotic that exhibits minimal systemic absorption through the skin and mucous membranes. This limits the spectrum of documented adverse reactions primarily to the site of use.


Adverse Reactions by System Organ Class and Frequency

Official regulatory documents classify adverse reactions predominantly within the following System Organ Classes:

  • Immune system disorders: Associated with hypersensitivity reactions (allergic response to the medication).
  • Skin and subcutaneous tissue disorders: Pertains to reactions at the site of topical application.
  • Gastrointestinal disorders: Applies to localized reactions observed during oromucosal administration (mouth/throat use).

Localized reactions, such as local irritation and local hypersensitivity reactions, are the most commonly documented effects. The occurrence of serious allergic reactions, including anaphylactic shock, is listed as rare.


Safety Restrictions and Limitations

Safety constraints documented in regulatory labeling emphasize the nature and route of the medicine:

  • Contraindication: The medicine is formally contraindicated in any individual with a documented known hypersensitivity to Tyrothricin or any of the preparation's excipients.
  • Route Restriction: Use is strictly limited to local application (topical or oromucosal) and must not be administered by injection.
  • Systemic Safety: Due to minimal systemic absorption, official regulatory documents generally do not specify safety considerations or dosage adjustments related to systemic organ function, such as in cases of mild or moderate hepatic or renal impairment.

This structure ensures that the primary focus of safety consideration remains on preventing allergic responses and ensuring appropriate, localized use.

Overdose and Emergency Response

Overdose Scope

Feature Official Regulatory Statement
Documented Overdose Presentations Nausea and vomiting may occur, primarily resulting from the accidental ingestion of larger amounts of co-formulated excipients, such as quaternary ammonium compounds, in lozenge formulations. Local irritation may result from high-dose, repeated administration.
Physiological Systems Affected Potential effects on the Central Nervous System and Cardiovascular System are documented but only if a readily absorbed, co-formulated active substance, such as Lidocaine, is ingested in overdose.
Exposure-related Factors Systemic overdose with Tyrothricin is considered clinically unlikely upon approved oral or topical application, as the active substance is hardly absorbed from the gastrointestinal tract.
When to Seek Medical Help If overdose is suspected or if intoxication symptoms develop, the patient shall be monitored carefully under medical supervision.

Official Overdose Management Statements

  • Symptomatic Management: Management of overdose shall be symptomatic and should comprise supportive measures. Due to potential excipients, milk or whipped egg white in water is recommended for certain accidental ingestions, and alcohol should be avoided.
  • Antidote Availability: No specific antidote is known for Tyrothricin or commonly co-formulated local anesthetics.
  • Avoided Procedures: For accidental ingestion of specific excipients, induced vomiting and gastric lavage should be avoided.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by the official assessment that systemic toxicity from the active ingredient is clinically unlikely, constraining the risk to local effects or effects from co-formulated substances. Emergency actions are dictated by the requirement for careful monitoring and the application of symptomatic and supportive measures if signs of intoxication become apparent, while providing explicit instructions on which procedural actions should be taken or avoided during initial management.

Therapeutic Uses of Herit

Main Uses of Herit

Herit is an iron-based medication primarily used for the treatment and prevention of iron deficiency and iron deficiency anemia. Iron is an essential mineral that the body requires to produce hemoglobin, a protein in red blood cells that enables them to carry oxygen throughout the body. When iron levels are insufficient, the body cannot produce enough healthy red blood cells, leading to various physiological symptoms.

Iron Deficiency Anemia

The primary indication for Herit is the management of iron deficiency anemia. This condition occurs when iron stores are depleted to the point that hemoglobin production is significantly impaired. It may be caused by several factors, including:

  • Inadequate dietary intake of iron.
  • Chronic blood loss.
  • Increased physiological demand for iron during specific life stages.
  • Malabsorption issues where the digestive tract cannot efficiently process iron from food.

Latent Iron Deficiency

Herit is also used to treat latent iron deficiency. This is a stage where iron stores (ferritin) are low, but hemoglobin levels remain within the normal range. Treating iron deficiency at this stage can prevent the progression to clinical anemia.

Benefits and Physiological Impact

The benefit of Herit lies in its ability to restore systemic iron levels, which supports several vital bodily functions.

Restoration of Hemoglobin Levels

By providing a concentrated source of iron, Herit facilitates the synthesis of hemoglobin. As hemoglobin levels normalize, the blood's oxygen-carrying capacity improves, which can help alleviate common symptoms associated with anemia, such as:

  • Persistent fatigue and generalized weakness.
  • Shortness of breath during physical exertion.
  • Dizziness or lightheadedness.
  • Pale skin and brittle nails.

Support for Metabolic Processes

Beyond hemoglobin production, iron is a critical component of myoglobin, a protein that stores oxygen in muscle cells, and various enzymes involved in energy metabolism and DNA synthesis. Adequate iron levels supported by Herit contribute to maintaining muscle function and overall cellular energy production.

Cognitive and Physical Performance

Maintaining sufficient iron levels is important for cognitive health and physical stamina. Restoring iron balance can help improve concentration and reduce the physical exhaustion that often accompanies depleted iron stores, supporting a patient's ability to engage in daily activities.

Eligibility and Restrictions for Use

Who can and cannot use Herit?

The eligibility for Herit (Tyrothricin) is strictly defined by official regulatory documents, focusing on populations for whom use is contraindicated or restricted.

Contraindications and Restrictions

The medicine must not be used by individuals with a documented hypersensitivity to Tyrothricin or any of its excipients. Use is also contraindicated if a viral or fungal infection is suspected in the application area, as the medicine is a purely antibacterial agent.

Population Eligibility Status
Children Prohibited for children under 3 years (lozenge forms). Safety and efficacy have not been established for children under 13 years (spray forms).
Adults/Adolescents Eligible for use under standard labeled conditions (typically 12 or 13 years).
Pregnancy/Lactation Not recommended due to a formal lack of available clinical data on use during pregnancy or breastfeeding.

Certain formulations impose additional restrictions. The presence of alcohol excipients requires caution for high-risk groups, including patients with liver disease (hepatic impairment) or epilepsy. Use may also be restricted for patients with hereditary metabolic disorders or uncontrolled diabetes when sugar excipients are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Herit contains the active substance Tyrothricin, a polypeptide antibiotic formulated exclusively for localized topical application to the skin or mucous membranes. Official regulatory documentation, including scientific monographs and government-approved labels, confirms that Tyrothricin is characterized by negligible systemic absorption.

This crucial pharmacological profile dictates the overall interaction structure for Herit. Due to the minimal to non-existent levels of the medicine entering the bloodstream, the risk of classic systemic drug-drug interactions is considered minimal or absent. Consequently, no clinically relevant systemic interactions are documented in official prescribing information concerning metabolic pathways (such as CYP enzymes), drug transporters (like P-gp), or exposure modification (altered AUC or Cmax).

No formal contraindications based on interaction risk with systemic medicines are listed in regulatory sources.

The only interaction-related constraint cited in official labeling is the local co-administration restriction. This restriction requires that other topical preparations should not be applied simultaneously to the exact site where Herit is being used. This is a procedural constraint designed to prevent local interference at the site of administration, rather than a systemic interaction affecting the body's clearance pathways. No mandatory time-separation rules for systemic medicines are required.

Mechanism of Action

How Herit Works

Herit's mechanism of action relies on a dual-component physical and functional attack directed at the bacterial cell membrane in susceptible microorganisms. The action is strictly localized to the application site due to the molecule's inability to penetrate tissue and its intrinsic cytotoxicity toward mammalian cells.

The first component, Tyrocidine, is a membrane destabilizer. It physically inserts into the lipid bilayer of the bacterium, causing structural disruption and permeabilization. This direct lytic action results in the uncontrolled leakage of essential intracellular contents, which initiates the bactericidal cascade.

Simultaneously, the second component, Gramicidin, complements this effect by integrating into the membrane to form ion-conducting channels. This structural modification leads to the rapid, uncontrolled efflux of critical cations, primarily potassium ( K^+). The resulting depletion of the ion gradient instantly collapses the bacterial cell's electrochemical potential, preventing energy generation (ATP synthesis) and accelerating cell death.

This mechanism concentrates the bactericidal activity locally, confining the resultant microbial load reduction to the superficial tissues.

Dosage and Administration Information

How Herit is Used

Herit, which contains the polypeptide antibiotic Tyrothricin, is intended solely for topical administration to ensure its activity is concentrated at the site of application. The medicine is utilized in two primary ways based on the formulation: oromucosal (for the mouth and throat) via lozenges or sprays, and cutaneous (for the skin) via solutions, creams, or powders.


Labeled Dosing and Administration

The following patterns and steps define the typical application of Herit.

Usage Guideline Standard Instructions
Route Focus Strictly topical (oromucosal or cutaneous); systemic use is prohibited.
Oromucosal Dosing Adults typically receive one lozenge per dose, with total daily intake restricted, often not to exceed eight lozenges in 24 hours.
Application Frequency Lozenges are generally administered on a divided daily schedule, often at intervals of approximately three hours between doses. Topical skin forms are applied two to three times daily.
Specific Technique Lozenges must be allowed to dissolve slowly in the mouth to maximize contact time; they must not be chewed or swallowed whole.

Duration and Special Populations

Treatment with Herit is characterized as a short-term course, usually lasting five to seven consecutive days. Administration may continue for approximately one week after symptoms have visibly subsided to support a complete regimen. For the oromucosal preparations, a minimum age restriction applies, generally allowing use for children aged three years and above. If a scheduled dose is missed, the regular dosing schedule is continued without taking a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Herit (Tyrothricin)


Evidence for Localized Mouth and Throat Discomfort

Research exploring the use of Herit was studied for conditions characterized by fluctuating or episodic manifestations, such as localized discomfort in the mouth and throat. These studies included the use of short-term, randomized controlled trials (RCTs). The trials was evaluated in adults who were experiencing conditions involving periods of heightened symptoms, such as pain and difficulty swallowing. Researchers monitored patient-reported outcomes describing perceived discomfort and the timing of changes in symptom intensity.

The findings describe patterns observed in the studies in terms of pain levels and ease of swallowing. However, the evidence base is complex because Tyrothricin was observed in many clinical trials as a component of a fixed-combination product. This means that the findings describe group patterns, not personal outcomes, and it is not yet clear whether the findings clearly reflect the contribution of the Tyrothricin component in every study. The follow-up durations were limited in these studies, typically focusing on the measurement of short-term symptom changes over approximately 72 hours.

Evidence for Superficial Skin Contamination and Lesions

The use of Herit for superficial bacterial contamination on the skin was evaluated in research exploring short-term symptom changes related to conditions involving outcomes reflecting daily functioning or activity level. The evidence includes small-scale clinical trials and extensive laboratory analyses (in vitro studies) that research describes the antimicrobial spectrum of the active ingredient. Researchers monitored outcomes such as the size of the affected area and scores related to the healing of the skin surface. The laboratory evidence data show patterns related to Tyrothricin’s activity primarily against Gram-positive strains.

A key limitation is that the sample sizes were modest in the clinical trials that focused on skin healing. Also, the follow-up durations were limited, typically spanning only the acute healing phase, providing limited information for long-term outcomes or the risk of future contamination.

What Research Gaps and Uncertainties Remain

The research for Herit presents several areas where certainty remains low. A major uncertainty involves the degree to which Tyrothricin was associated with findings observed in the studies when it is part of a fixed-combination product. Because the comparative evidence is limited for the isolated ingredient versus a placebo in all contexts, research provides limited insight into its singular action. Data for certain groups remain insufficient, particularly for pediatric patients (children) and those with complex, pre-existing comorbid conditions.

Frequently Asked Questions (FAQ)

Common questions about Herit (FAQ)

Q: Is Herit a new type of drug or has it been around for a while?

A: Herit’s active substance, Tyrothricin, is a polypeptide antibiotic that is of natural origin, isolated from the soil bacterium Brevibacillus parabrevis. According to official information, this substance has been used in medical applications for several decades.


Q: Are there any common reasons people stop taking Herit?

A: Reasons for discontinuing Herit are not formally documented in detail. However, the medicine is formally contraindicated (should not be used) if a known hypersensitivity or allergic reaction occurs. Local irritation and gastrointestinal disorders are among the most frequently reported side effects.


Q: Is it normal to feel tired when starting Herit?

A: Official regulatory documents list known side effects by system organ class, such as allergic reactions, skin effects, and gastrointestinal issues. Tiredness or fatigue is not typically listed as a common or known side effect in the official labeling for this topically-acting medicine.


Q: How long does Herit stay in your system after you stop taking it?

A: Because Herit is formulated strictly for topical use (on the skin or mucous membranes), the active substance has negligible systemic absorption. This means the amount that enters the bloodstream is minimal, and regulatory information typically does not define a specific half-life or clearance time for the compound in the body.


Q: Does Herit interact with vitamins or herbal supplements?

A: Official labeling confirms that the risk of systemic drug-drug interactions (including with vitamins or most herbal supplements) is minimal or absent due to the negligible systemic absorption of Herit. The only interaction-related constraint is a procedural one: the restriction requires that other topical preparations should not be applied to the exact same site where Herit is being used.


Q: Are there specific symptoms that mean Herit might not be working?

A: The official product information recommends that if symptoms persist or worsen after a short course of treatment, the administration should be discontinued. If this happens, the condition should be re-evaluated by a healthcare professional, as the treatment regimen is typically short-term (five to seven days).


Q: Can Herit cause weight gain or weight loss?

A: Official regulatory documents categorize and list common side effects. Weight gain or weight loss are not listed among the documented adverse reactions for this medicine.


Q: What did the original clinical trials for Herit show?

A: Clinical studies primarily focused on short-term patient-reported outcomes, particularly for localized discomfort and changes in symptom intensity. Research follow-up durations were often limited to the acute phase, and many trials studied Herit's active substance as part of a fixed-combination product.


Q: Is Herit known to cause mood changes or emotional side effects?

A: Official labeling includes a safety profile derived from clinical data. Mood changes or emotional side effects are not listed under the documented adverse reactions for this medicine.


Q: Is Herit a controlled substance?

A: No. The active ingredient in Herit, Tyrothricin, is classified as a polypeptide antibiotic and is not scheduled or classified as a narcotic or controlled substance by major regulatory bodies.


Q: What is the experience of people taking Herit for more than a year?

A: Herit is explicitly characterized in official information as a short-term course treatment, typically used for only five to seven consecutive days. Research follow-up durations were also limited, meaning there is insufficient clinical data available concerning long-term use.


Q: Are there any restrictions on activity while taking Herit?

A: For the lozenge form, the official administration technique requires that the lozenge must be allowed to dissolve slowly in the mouth to work effectively. This implies a temporary restriction on activities like chewing, eating, or drinking until the lozenge has fully dissolved.


Q: Does taking Herit with food reduce the chance of side effects?

A: Official labeling does not state that taking Herit with food reduces side effects. It focuses on the proper administration technique for lozenges, which must be dissolved slowly in the mouth to ensure therapeutic benefit.


Q: Does the efficacy of Herit decrease over time?

A: Herit is indicated for short-term use only. Official regulatory information does not contain data or statements that address the topic of reduced efficacy, sometimes referred to as tolerance or tachyphylaxis, which is often associated with long-term use.


Q: Are there any foods or drinks to avoid while taking Herit?

A: Official labeling does not list specific foods or drinks that must be avoided while using Herit. For the lozenge forms, the instructions are simply to allow the medicine to dissolve slowly in the mouth and not to chew or swallow it whole.


Q: Are headaches a frequent side effect of Herit?

A: Headaches are not listed among the common or frequent side effects documented in official regulatory documents for this topically-applied medicine.


Q: Does Herit require regular blood tests while taking it?

A: Due to its minimal systemic absorption, the medicine primarily acts locally. For this reason, official regulatory documents generally do not specify the need for systemic safety monitoring like regular blood tests.


Q: How does Herit affect sleep patterns?

A: Official regulatory documents review all side effects reported during clinical trials and post-market use. Disruptions to sleep patterns are not listed among the documented adverse reactions for this topically-applied medicine.


Q: Can Herit be taken alongside supplements like melatonin or magnesium?

A: The risk of systemic drug-drug interactions with supplements like melatonin or magnesium is minimal or absent because of Herit's negligible systemic absorption. The only constraint is ensuring no other topical products are applied to the same site simultaneously.


Q: Are there any known interactions between Herit and common cold medicines?

A: Official labeling confirms that due to Herit's negligible systemic absorption, no clinically relevant systemic interactions (such as with common cold medicines) are documented. The risk of these types of interactions is minimal or absent.


Q: What's the difference between the brand name Herit and its active ingredient?

A: Herit is the brand name given to the finished medicinal product by the manufacturer. Tyrothricin is the active pharmaceutical ingredient that is contained within the brand-name product and is responsible for its antimicrobial action.


Q: Are people with chronic conditions able to take Herit?

A: While use is generally permitted, official warnings advise caution for high-risk groups with pre-existing conditions. Specifically, patients with liver disease or epilepsy may need caution if alcohol excipients are present, and those with uncontrolled diabetes if sugar excipients are used in the formulation.

How should Herit be stored and disposed of?

The official storage and disposal guidelines for Herit (Tyrothricin) are governed by regulatory documents to preserve the product's stability and prevent environmental contamination.

Storage Requirements

Herit must be stored below a maximum temperature of 25 C in a dry and well-ventilated place, with mandatory protection from humidity. The container must be kept tightly closed and stored safely out of the sight and reach of children. To maintain integrity, the product should also be stored apart from foodstuffs and incompatible materials.


Disposal Instructions

Unused or expired Herit must not be discharged to sewer systems or drains to avoid environmental contamination. Disposal is strictly required via controlled incineration or removal to a licensed chemical destruction plant in accordance with official local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Herit found in:

A-Z Index: